8-KEarnings & ResultsExhibits & Filings

ELI LILLY & Co 8-K Report, Financial Results (Jul 30, 2019)

Filed July 30, 2019For Securities:LLY

Summary

Eli Lilly and Company (LLY) filed an 8-K on July 30, 2019, primarily to report their second-quarter financial results for the period ended June 30, 2019. The key information is contained within an attached press release (Exhibit 99.1), which is being furnished rather than formally filed. Investors should refer to this press release for detailed financial performance data, operational highlights, and any forward-looking statements or guidance the company provided for the second quarter of 2019. While the 8-K itself is a brief notification of the results announcement, the attached press release serves as the critical document for understanding Lilly's performance during the second quarter. This includes revenue figures, earnings per share, and potentially updates on key product sales and pipeline developments that would be of significant interest to shareholders and potential investors assessing the company's current financial health and future prospects.

Key Highlights

  • 1Eli Lilly & Co. (LLY) filed an 8-K on July 30, 2019, to announce its second-quarter financial results for the period ending June 30, 2019.
  • 2The detailed financial results are provided in an attached press release (Exhibit 99.1).
  • 3The information is furnished and not formally filed under Section 18 of the Exchange Act, meaning it's not subject to the same liability provisions.
  • 4Investors should consult Exhibit 99.1 for specifics on revenue, earnings, and operational performance.
  • 5The filing serves as an official notification of the company's Q2 2019 earnings announcement.
  • 6No other material events or new financial statements were disclosed in the 8-K itself, beyond the earnings release.

Frequently Asked Questions

The main purpose of this 8-K filing is to officially notify the public and investors that Eli Lilly and Company has released its financial results for the second quarter of 2019, which ended on June 30, 2019. The detailed results are included in an attached press release.

The actual financial details, including operating results, revenue, and earnings for the second quarter of 2019, are located in Exhibit 99.1, which is the press release attached to this 8-K filing. You should review this press release for comprehensive information.

No, the information in Item 2.02 of this 8-K, including the attached press release, is being 'furnished' rather than 'filed'. This means it is not subject to the liabilities of Section 18 of the Securities Exchange Act of 1934, though it is still publicly available.

This 8-K filing itself does not provide new guidance. However, the attached press release (Exhibit 99.1) is the document that would typically contain any updated financial guidance or outlook provided by Eli Lilly for future periods based on their second-quarter performance.